This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

High Hopes for Ketamine Depression Treatments

Stocks in this article: JNJ RHHBY AZN

Plus, two other glutamate-based agents are in development for depression by Roche (RHHBY). And Johnson & Johnson (JNJ), has esketamine, an intranasal form of the drug, in phase II trials. Nasal delivery would be a big winner.

One would think it would be hard to make money off of a drug like ketamine that has been around for almost 50 years. But with the dearth of depression treatments that actually work and with drug companies shying away from developing new drugs that treat psychiatric  disorders, ketamine, with its long history as an anesthetic, is getting a hard look.

Research and current real-life, off-label use of the drug shows that most depressed patients definitely feel effects when ketamine starts flowing into their veins. Right away. This in contrast to the standard antidepressant pill, which can take four to six weeks to work, and even then, not often all that great.

Here's how treatment works: A small dose is infused into a patient over 40 minutes. After about 10 minutes, patients report feeling as if the weight of their depression is being lifted so much so that they are levitating, flying, floating above the bed.

People come down from the intense high in about two hours, but the antidepressant effects stick around long after the relatively short half-life of two to four hours -- as long as four weeks, in some published trials. All effects seem to wear off after a while, though, and patients likely have to come back for new infusions every few weeks. At say, $500 or more a pop. Nice repeat business.

One start-up company, Ketanetics, is creating a network of physicians who offer their "ketamine-based treatment algorithm" to help "physicians quickly incorporate ketamine-infusion therapy into their practices." The Newburyport, Mass.-based company is co-founded by well-known psychiatrist Keith Ablow, who has appeared as an expert on many national television programs, such as Dr. Oz, Oprah and the O'Reilly Factor.

If ketamine is a success, it may encourage scientists to look outside the lab, and into dance clubs, veterinary clinics -- and even the streets -- for the next blockbuster drug.

At the time of publication, the author had no position in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,805.82 +27.67 0.16%
S&P 500 2,072.96 +11.73 0.57%
NASDAQ 4,773.0150 +24.6190 0.52%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs